Bêta-thalassémie majeure : actualisation de la prise en charge en médecine bucco-dentaire

Sarah Millot; Henri Woimant; Anne-Laure Ejeil; Jean-Luc Charrier

doi:10.1051/mbcb/2011001

Home

All issues

Volume 17 / No 1 (Février 2011)

Med Buccale Chir Buccale, 17 1 (2011) 51-54

References

Open Access

Observation clinique

Issue		Med Buccale Chir Buccale Volume 17, Number 1, Février 2011


Page(s)		51 - 54
Section		Observations cliniques / Case reports
DOI		https://doi.org/10.1051/mbcb/2011001
Published online		21 February 2011

Higgs DR, Thein SL, Woods WG. The molecular pathology of the thalassemias. In: The thalassemia syndromes (pp. 133-91), 4^th ed. Blackwell Science, Oxford, 2001. [Google Scholar]
Pootrakul P, Sirankapracha P, Hemsorach S. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in Thai patients with thalassemia. Blood 2000;96:2606-12. [PubMed] [Google Scholar]
Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005;353:1135-46. [CrossRef] [PubMed] [Google Scholar]
Lucarelli G, Andreani M, Angelucci E. The cure of thalassemia by bone marrow transplantation.Blood Rev 2002;16:81-5. [Google Scholar]
Cunningham MJ, Macklin EA, Cohen NA. Complications of β-thalassemia major in north America. Blood 2004;104:34-9. [CrossRef] [PubMed] [Google Scholar]
Syndromes thalassémiques majeurs et intermédiaires: protocole national de diagnostic et de soins pour une maladie rare. Haute Autorité de Santé, Guide affection longue durée, 2008. [Google Scholar]
Oliveri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61. [PubMed] [Google Scholar]
Borgna-Pignatti C, Cappellini MD, de Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in deferoxamine or deferiprone treated patients with thalassemia major. Blood 2006;1;107:3733-7. [Google Scholar]
Emploi des vasoconstricteurs en odonto-stomatologie. Recommandations. Med Buccale Chir Buccale 2003;9;2:65-94. [Google Scholar]
Prise en charge des patients sous traitements anti-vitamine K en chirurgie bucco-dentaire. Recommandations. Med Buccale Chir Buccale 2006;12:187-212. [Google Scholar]
Fragatou S, Tsourveloudis I, Manesis G. Incidence of hepatocellular carcinoma in a thalassemia unit. Hemoglobin 2010;34:221-6. [CrossRef] [PubMed] [Google Scholar]
Cadili A, Gara C. Complications of splenectomy. Am J Med 2008;121:371-5. [CrossRef] [PubMed] [Google Scholar]
Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci PM. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassemia intermedia. Br J Haematol 2000;111:467-73. [CrossRef] [PubMed] [Google Scholar]
Jung S, Garret-Bernardin A, Grollemund B, Cojean N, Lutz P, Manière MC, Féki A. Manifestations dento-maxillo-faciales chez un enfant atteint d’une béta-thalassémie majeure traitée par greffe de cellules souches hématopoïétiques. A propos d’un cas. Med Buccale Chir Buccale 2006;12;3:163-70. [CrossRef] [Google Scholar]
Van Dis M, Langlais R. The thalassemias : oral manifestations and complications. Oral Surg Oral Med Oral Pathol 1986;62:229-33. [CrossRef] [PubMed] [Google Scholar]
Basu S, Kumar A. Hair-on-end appearance in radiograph of skull and facial bones in a case of beta thalassemia. Br J Haematol 2008;144:807. [CrossRef] [PubMed] [Google Scholar]
Chatterjee R, Bajoria R. Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment. Hemoglobin 2009;33 suppl 1:S136-8. [Google Scholar]
Voskaridou E, Terpos, Spina G, Palermos J, Rahemtulla A, Loutradi ALoukopoulos D. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassemia. Br J Haematol 2003;123:730-7. [CrossRef] [PubMed] [Google Scholar]
Leung TF, Chu Y, Lee V, Leung WK, Shing MM, Li CK. Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits. Hemaglobin 2009;33:361-9. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.

[1] Higgs DR, Thein SL, Woods WG. The molecular pathology of the thalassemias. In: The thalassemia syndromes (pp. 133-91), 4^th ed. Blackwell Science, Oxford, 2001. [Google Scholar]

[2] Pootrakul P, Sirankapracha P, Hemsorach S. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in Thai patients with thalassemia. Blood 2000;96:2606-12. [PubMed] [Google Scholar]

[3] Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005;353:1135-46. [CrossRef] [PubMed] [Google Scholar]

[4] Lucarelli G, Andreani M, Angelucci E. The cure of thalassemia by bone marrow transplantation.Blood Rev 2002;16:81-5. [Google Scholar]

[5] Cunningham MJ, Macklin EA, Cohen NA. Complications of β-thalassemia major in north America. Blood 2004;104:34-9. [CrossRef] [PubMed] [Google Scholar]

[6] Syndromes thalassémiques majeurs et intermédiaires: protocole national de diagnostic et de soins pour une maladie rare. Haute Autorité de Santé, Guide affection longue durée, 2008. [Google Scholar]

[7] Oliveri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61. [PubMed] [Google Scholar]

[8] Borgna-Pignatti C, Cappellini MD, de Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in deferoxamine or deferiprone treated patients with thalassemia major. Blood 2006;1;107:3733-7. [Google Scholar]

[9] Emploi des vasoconstricteurs en odonto-stomatologie. Recommandations. Med Buccale Chir Buccale 2003;9;2:65-94. [Google Scholar]

[10] Prise en charge des patients sous traitements anti-vitamine K en chirurgie bucco-dentaire. Recommandations. Med Buccale Chir Buccale 2006;12:187-212. [Google Scholar]

[11] Fragatou S, Tsourveloudis I, Manesis G. Incidence of hepatocellular carcinoma in a thalassemia unit. Hemoglobin 2010;34:221-6. [CrossRef] [PubMed] [Google Scholar]

[12] Cadili A, Gara C. Complications of splenectomy. Am J Med 2008;121:371-5. [CrossRef] [PubMed] [Google Scholar]

[13] Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci PM. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassemia intermedia. Br J Haematol 2000;111:467-73. [CrossRef] [PubMed] [Google Scholar]

[14] Jung S, Garret-Bernardin A, Grollemund B, Cojean N, Lutz P, Manière MC, Féki A. Manifestations dento-maxillo-faciales chez un enfant atteint d’une béta-thalassémie majeure traitée par greffe de cellules souches hématopoïétiques. A propos d’un cas. Med Buccale Chir Buccale 2006;12;3:163-70. [CrossRef] [Google Scholar]

[15] Van Dis M, Langlais R. The thalassemias : oral manifestations and complications. Oral Surg Oral Med Oral Pathol 1986;62:229-33. [CrossRef] [PubMed] [Google Scholar]

[16] Basu S, Kumar A. Hair-on-end appearance in radiograph of skull and facial bones in a case of beta thalassemia. Br J Haematol 2008;144:807. [CrossRef] [PubMed] [Google Scholar]

[17] Chatterjee R, Bajoria R. Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment. Hemoglobin 2009;33 suppl 1:S136-8. [Google Scholar]

[18] Voskaridou E, Terpos, Spina G, Palermos J, Rahemtulla A, Loutradi ALoukopoulos D. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassemia. Br J Haematol 2003;123:730-7. [CrossRef] [PubMed] [Google Scholar]

[19] Leung TF, Chu Y, Lee V, Leung WK, Shing MM, Li CK. Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits. Hemaglobin 2009;33:361-9. [CrossRef] [Google Scholar]